Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Ovarian Neoplasms 3Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Penile Neoplasms 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 19Paclitaxel 10Carboplatin 10Magnetic Resonance Spectroscopy 9Docetaxel 9Cyclophosphamide 9Specimen Handling 8Cisplatin 8Gemcitabine 7Drug Therapy 7sargramostim 6Pemetrexed 6Nivolumab 6fludarabine 5aldesleukin 5Trastuzumab 5Bevacizumab 5Taxes 4Fluorouracil 4Blood Specimen Collection 4Amifostine 4veliparib 3pegfilgrastim 3Topotecan 3Irinotecan 3IFL protocol 3Fluorodeoxyglucose F18 3Etoposide 3Early Intervention, Educational 3tariquidar 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × BAY 1895344 × Gynecologic × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡